Co-Founder, Ceo
CurrentThe “Holy Grail” in cancer is to kill cancer cells, but not kill healthy cells. Pharma companies have historically searched for natural biomarkers on cancer cells to therapeutically target them. Earli turns that approach on its head. Instead of searching for natural targets, Earli creates programmable genetic constructs that enter cancer cells and force.